Logo image of IIN

INTRICON CORP (IIN) Stock Fundamental Analysis

NASDAQ:IIN - Nasdaq - US46121H1095 - Common Stock

24.24  +0.01 (+0.04%)

After market: 24.25 +0.01 (+0.04%)

Fundamental Rating

4

IIN gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. The financial health of IIN is average, but there are quite some concerns on its profitability. IIN is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IIN was profitable.
IIN Yearly Net Income VS EBIT VS OCF VS FCFIIN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 2M -2M 4M -4M 6M 8M

1.2 Ratios

Industry RankSector Rank
ROA -1.17%
ROE 1.03%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IIN Yearly ROA, ROE, ROICIIN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 10 -10 -20

1.3 Margins

Industry RankSector Rank
OM 1.27%
PM (TTM) -1.17%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IIN Yearly Profit, Operating, Gross MarginsIIN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 10 20 30

More info and screens

6

2. Health

2.1 Basic Checks

IIN has more shares outstanding than it did 1 year ago.
IIN has a worse debt/assets ratio than last year.
IIN Yearly Shares OutstandingIIN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M
IIN Yearly Total Debt VS Total AssetsIIN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

IIN has an Altman-Z score of 5.50. This indicates that IIN is financially healthy and has little risk of bankruptcy at the moment.
There is no outstanding debt for IIN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.5
ROIC/WACCN/A
WACCN/A
IIN Yearly LT Debt VS Equity VS FCFIIN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 3.20 indicates that IIN has no problem at all paying its short term obligations.
A Quick Ratio of 2.01 indicates that IIN has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 3.2
Quick Ratio 2.01
IIN Yearly Current Assets VS Current LiabilitesIIN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 1200.00% over the past year.
IIN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 14.50% yearly.
Looking at the last year, IIN shows a quite strong growth in Revenue. The Revenue has grown by 11.90% in the last year.
The Revenue has been growing by 12.66% on average over the past years. This is quite good.
EPS 1Y (TTM)1200%
EPS 3Y-5.9%
EPS 5Y14.5%
EPS Q2Q%-196.47%
Revenue 1Y (TTM)11.9%
Revenue growth 3Y3.21%
Revenue growth 5Y12.66%
Sales Q2Q%4.06%

3.2 Future

Based on estimates for the next years, IIN will show a very strong growth in Earnings Per Share. The EPS will grow by 85.86% on average per year.
The Revenue is expected to grow by 13.78% on average over the next years. This is quite good.
EPS Next Y-13.69%
EPS Next 2Y38.86%
EPS Next 3Y68.37%
EPS Next 5Y85.86%
Revenue Next Year10.43%
Revenue Next 2Y14.04%
Revenue Next 3Y13.68%
Revenue Next 5Y13.78%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
IIN Yearly Revenue VS EstimatesIIN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
IIN Yearly EPS VS EstimatesIIN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2 4 6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 44.07, IIN can be considered very expensive at the moment.
The average S&P500 Price/Earnings ratio is at 29.62. IIN is valued slightly more expensive when compared to this.
With a Price/Forward Earnings ratio of 22.86, IIN is valued on the expensive side.
When comparing the Price/Forward Earnings ratio of IIN to the average of the S&P500 Index (22.70), we can say IIN is valued inline with the index average.
Industry RankSector Rank
PE 44.07
Fwd PE 22.86
IIN Price Earnings VS Forward Price EarningsIIN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 28.47
IIN Per share dataIIN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

IIN's earnings are expected to grow with 68.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)3.04
EPS Next 2Y38.86%
EPS Next 3Y68.37%

More info and screens

0

5. Dividend

5.1 Amount

IIN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTRICON CORP

NASDAQ:IIN (5/24/2022, 8:00:02 PM)

After market: 24.25 +0.01 (+0.04%)

24.24

+0.01 (+0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)06-03 2022-06-03/amc
Earnings (Next)08-08 2022-08-08
Inst Owners0%
Inst Owner Change0%
Ins Owners2.54%
Ins Owner Change0%
Market Cap225.49M
Analysts84
Price Target25.5 (5.2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 44.07
Fwd PE 22.86
P/S 1.78
P/FCF N/A
P/OCF N/A
P/B 2.41
P/tB N/A
EV/EBITDA 28.47
EPS(TTM)0.55
EY2.27%
EPS(NY)1.06
Fwd EY4.38%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS13.6
BVpS10.06
TBVpSN/A
PEG (NY)N/A
PEG (5Y)3.04
Profitability
Industry RankSector Rank
ROA -1.17%
ROE 1.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 1.27%
PM (TTM) -1.17%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.2
Quick Ratio 2.01
Altman-Z 5.5
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1200%
EPS 3Y-5.9%
EPS 5Y14.5%
EPS Q2Q%-196.47%
EPS Next Y-13.69%
EPS Next 2Y38.86%
EPS Next 3Y68.37%
EPS Next 5Y85.86%
Revenue 1Y (TTM)11.9%
Revenue growth 3Y3.21%
Revenue growth 5Y12.66%
Sales Q2Q%4.06%
Revenue Next Year10.43%
Revenue Next 2Y14.04%
Revenue Next 3Y13.68%
Revenue Next 5Y13.78%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A